regulatory
confidence high
sentiment negative
materiality 0.60
Calidi Biotherapeutics hit with NYSE American notice; equity $3.1M vs $4.0M required
Calidi Biotherapeutics, Inc.
- NYSE American notice dated Sept 21, 2026: stockholders' equity of $3.1M at June 30, 2026 is below the $4.0M minimum required by Company Guide Section 1003(a)(ii).
- Standard was triggered because Calidi reported net losses in three of its four most recent fiscal years ended December 31, 2025.
- Company must submit a compliance plan by Oct 21, 2026 and regain compliance by March 21, 2028; it is not eligible for any Section 1003(a) exemption, including the $50M market-cap exemption.
- CLDI keeps trading on NYSE American but gets a '.BC' below-compliance designation; delisting proceedings would begin if no plan is filed or the plan is rejected.
- Management says it is reviewing options and expects to submit the plan on or before the NYSE American deadline; the notice does not affect business operations or SEC reporting.